MedChemExpress (MCE) 專注于為科學(xué)家提供高品質(zhì)的生物活性小分子化合物，化合物庫及各類試劑盒，總部位于美國新澤西。
• MedChemExpress (MCE) 產(chǎn)品作用于 20 多個熱門信號通路及研究領(lǐng)域的300多個細分靶點，擁有 10000 特異性抑制劑、激動劑，以及 50 活性化合物篩選庫；
• 我們堅持對所有產(chǎn)品進行嚴格質(zhì)檢，確保產(chǎn)品的高品質(zhì)和高純度；
• MedChemExpress (MCE) 產(chǎn)品已被數(shù)萬名科學(xué)家信賴，并被大量top文獻和*引用；
• 我們擁有專業(yè)的技術(shù)團隊追蹤前沿科研進展，不斷豐富各個靶點的特異性產(chǎn)品，堅持做 “您身邊的抑制劑大師”；
• MedChemExpress (MCE) 與眾多藥企和科研機構(gòu)保持深度合作；
• 大量產(chǎn)品有中國庫存，工作日 16:00 前訂單確保當(dāng)日發(fā)貨，次日送達。
MCE 中國站：www.MedChemExpress.cn
Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656
抑制劑，調(diào)節(jié)劑，API，天然產(chǎn)物，各種類型化合物庫
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | 2 mg；5 mg；10 mg |
|---|---|---|---|
| 貨號 | HY-12815 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
MCC950
產(chǎn)品活性：MCC950 是一種有效，選擇性的 NLRP3 抑制劑，在BMDMs 和 HMDMs中的IC50 分別為 7.5 nM 和 8.1 nM。
研究領(lǐng)域：Immunology/Inflammation
作用靶點：NOD-like Receptor (NLR)
In Vitro: MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. The effect of MCC950 on NLRP3 inflammasome activation is tested in mouse bone marrow derived macrophages (BMDM) and human monocyte derived macrophages (HMDM). The IC50 of MCC950 in BMDM is approximately 7.5 nM, while in HMDM it has a similar inhibitory capacity (IC50=8.1 nM). MCC950 also dose dependently inhibit IL-1β but not TNF-α secretion.MCC950 specifically blocks caspase-11-directed NLRP3 activation and IL-1β secretion upon stimulation of the non-canonical pathway. NLRC4-stimulated IL-1β and TNF-α secretion (as activated by Salmonella typhimurium) are not inhibited by MCC950 even at a concentration of 10 µM. MCC950 does not inhibit caspase-1 activation or IL-1β processing in response to S. typhimurium. The expression of pro-caspase-1 and pro-IL-1β in cell lysates is not substantially affected by MCC950 treatment.
In Vivo: MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells.
相關(guān)產(chǎn)品：MCC950 sodium | CY-09 | NOD-IN-1 | INF39 | Troxerutin | Nodinitib-1 | Arglabin | Dapansutrile | N4-Acetylcytidine triphosphate
采購中心
化工儀器網(wǎng)